J Mark Jackson

Summary

Publications

  1. ncbi Efficacy of extended-release 45 mg oral minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea
    J Mark Jackson
    Division of Dermatology, Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY, USA
    J Drugs Dermatol 12:292-8. 2013
  2. ncbi Topical rosacea therapy: the importance of vehicles for efficacy, tolerability and compliance
    J Mark Jackson
    Division of Dermatology, University of Louisville, Louisville, KY 40202, USA
    J Drugs Dermatol 10:627-33. 2011
  3. ncbi Mycophenolate mofetil for the treatment of chronic dermatitis: an open-label study of 16 patients
    J Mark Jackson
    University of Louisville, Division of Dermatology, Louisville, KY 40202, USA
    J Drugs Dermatol 9:356-62. 2010
  4. ncbi A randomized, investigator-blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/ clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris
    J Mark Jackson
    Division of Dermatology, University of Louisville, Louisville, KY 40202, USA
    J Drugs Dermatol 9:131-6. 2010
  5. ncbi TNF- alpha inhibitors
    J Mark Jackson
    University of Louisville Division of Dermatology, Dermatology Specialists Louisville, Kentucky 40202, USA
    Dermatol Ther 20:251-64. 2007
  6. ncbi Hepatitis C and the skin
    J Mark Jackson
    Division of Dermatology, University of Louisville School of Medicine, 444 South First Street, Louisville, KY 40202, USA
    Dermatol Clin 20:449-58. 2002
  7. ncbi Emerging infections in dermatology
    J Mark Jackson
    University of Louisville, Division of Dermatology, Dermatology Specialists, Louisville, KY 40202, USA
    Semin Cutan Med Surg 25:201-6. 2006
  8. ncbi Hydrocortisone butyrate 0.1% cream in the treatment of chronic dermatitis
    Joseph F Fowler
    University of Louisville School of Medicine, Kentucky, USA
    Cutis 75:125-31. 2005
  9. ncbi Pyoderma gangrenosum: an update
    Jeffrey P Callen
    Division of Dermatology, University of Louisville, 310 East Broadway, Louisville, KY 40202, USA
    Rheum Dis Clin North Am 33:787-802, vi. 2007
  10. ncbi Innovative treatments for chronic dermatitis
    J Mark Jackson
    University of Louisville, Division of Dermatology, Dermatology Specialists PSC, Louisville, Kentucky, USA
    Adv Dermatol 20:293-322. 2004

Collaborators

Detail Information

Publications15

  1. ncbi Efficacy of extended-release 45 mg oral minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea
    J Mark Jackson
    Division of Dermatology, Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY, USA
    J Drugs Dermatol 12:292-8. 2013
    ..This manuscript highlights the use of a new sustained-release low-dose minocycline 45 mg tablet, with or without azelaic acid, for the treatment of papulopustular rosacea...
  2. ncbi Topical rosacea therapy: the importance of vehicles for efficacy, tolerability and compliance
    J Mark Jackson
    Division of Dermatology, University of Louisville, Louisville, KY 40202, USA
    J Drugs Dermatol 10:627-33. 2011
    ....
  3. ncbi Mycophenolate mofetil for the treatment of chronic dermatitis: an open-label study of 16 patients
    J Mark Jackson
    University of Louisville, Division of Dermatology, Louisville, KY 40202, USA
    J Drugs Dermatol 9:356-62. 2010
    ..Trends in patient and investigator global assessments were analyzed with the fitting of models using generalized estimating equations (GEE)...
  4. ncbi A randomized, investigator-blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/ clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris
    J Mark Jackson
    Division of Dermatology, University of Louisville, Louisville, KY 40202, USA
    J Drugs Dermatol 9:131-6. 2010
    ..Combination products in which the individual components have different mechanisms of antimicrobial action have been shown in many disease states to provide the most effective therapy...
  5. ncbi TNF- alpha inhibitors
    J Mark Jackson
    University of Louisville Division of Dermatology, Dermatology Specialists Louisville, Kentucky 40202, USA
    Dermatol Ther 20:251-64. 2007
    ..The side effect profile and monitoring recommendations for these agents will also be discussed...
  6. ncbi Hepatitis C and the skin
    J Mark Jackson
    Division of Dermatology, University of Louisville School of Medicine, 444 South First Street, Louisville, KY 40202, USA
    Dermatol Clin 20:449-58. 2002
    ....
  7. ncbi Emerging infections in dermatology
    J Mark Jackson
    University of Louisville, Division of Dermatology, Dermatology Specialists, Louisville, KY 40202, USA
    Semin Cutan Med Surg 25:201-6. 2006
    ..The background, clinical presentation, diagnosis, and treatment of each of the 3 infections will be discussed...
  8. ncbi Hydrocortisone butyrate 0.1% cream in the treatment of chronic dermatitis
    Joseph F Fowler
    University of Louisville School of Medicine, Kentucky, USA
    Cutis 75:125-31. 2005
    ....
  9. ncbi Pyoderma gangrenosum: an update
    Jeffrey P Callen
    Division of Dermatology, University of Louisville, 310 East Broadway, Louisville, KY 40202, USA
    Rheum Dis Clin North Am 33:787-802, vi. 2007
    ..The diagnosis of PG is one of exclusion. The management of this disorder begins with treatment of any underlying disease and local or systemic glucocorticoids or immunomodulating therapies...
  10. ncbi Innovative treatments for chronic dermatitis
    J Mark Jackson
    University of Louisville, Division of Dermatology, Dermatology Specialists PSC, Louisville, Kentucky, USA
    Adv Dermatol 20:293-322. 2004
  11. ncbi Isotretinoin as a treatment for axillary granular parakeratosis
    Aaron K Compton
    University of Louisville, Kentucky, USA
    Cutis 80:55-6. 2007
    ..We conclude that treatment of axillary granular parakeratosis with isotretinoin is rapid and effective and should be considered in patients with no other contraindications to isotretinoin...
  12. ncbi Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial
    Alexa Boer Kimball
    Massachusetts General and Brigham and Women s Hospitals, Harvard Medical School, Boston, MA 02114, USA
    J Drugs Dermatol 6:299-306. 2007
    ..These results could translate into savings on both direct and indirect costs and improvements in health-related quality of life for patients with PsA...
  13. ncbi Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study
    Alice B Gottlieb
    Department of Dermatology, Tufts New England Medical Center, Boston, MA 02111 1533, USA
    J Dermatolog Treat 17:343-52. 2006
    ..To assess the efficacy and tolerability of etanercept to treat psoriatic arthritis...
  14. ncbi Case reports of etanercept in inflammatory dermatoses
    Robert Norman
    J Am Acad Dermatol 54:S139-42. 2006
    ..Treatment with etanercept substantially improved the clinical symptoms and quality of life in these patients, and may offer a therapeutic option for some patients with severe skin disorders...
  15. ncbi Treatment of recurrent Sweet's syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept
    Paul S Yamauchi
    J Am Acad Dermatol 54:S122-6. 2006